Dipartimento di Scienze Farmaceutiche, Università di Modena e R.E., Via Campi 183 41100 Modena, Italy.
Expert Opin Ther Pat. 2010 Nov;20(11):1603-7. doi: 10.1517/13543776.2011.527333. Epub 2010 Oct 12.
The patent claims inhibitors of ghrelin-O-acyltransferase enzyme. These inhibitors were designed as bisubstrate analogs of the enzymatic reaction and were coupled with one of the peptides able to cross cell membranes, the 11-mer Tat peptide. The compound GO-CoA-Tat was studied in vitro and in vivo; after intraperitoneal administration, it enhances insulin response to a glucose load and leads to a statistically significant weight loss in mouse fed with a high fat diet.
该专利要求保护 Ghrelin-O-酰基转移酶抑制剂。这些抑制剂被设计为酶反应的双底物类似物,并与能够穿过细胞膜的肽之一,即 11 肽 Tat 肽偶联。研究了化合物 GO-CoA-Tat 的体外和体内活性;腹腔给药后,它增强了胰岛素对葡萄糖负荷的反应,并导致高脂肪饮食喂养的小鼠体重出现统计学显著下降。